[Edaily Starin KIM HYUNSIK Reporter] The group ENHYPEN (Jeongwon, Jay, Jake, Seonghun, Seonwoo, Niki) is set to kick off their comeback activities. ENHYPEN (Photo courtesy of Belief Lab)New Album Cover (Photo courtesy of Belief Lab)According to their agency,Belief Lab, on the 26th, ENHYPEN will make a comeback on the 20th of next month with the single “THE SIN: PARALLEL WORLD.” The track will be released at 2:00 p.m. on the day of the comeback via various online music platforms, and the physical album will be released three days later, on the 23rd. Previously, with their mini-albums “THE SIN: VANISH” and “THE SIN: BLISS,” released in January and August, respectively, ENHYPEN told the story of a couple who broke taboos and fled for love in a world where humans and vampires coexist. In their previous works, they depicted the process by which the lovers—who had chosen to flee—came to realize that simply being together was a blessing. Their new release, “THE SIN: Parallel World,” unveiled just three months later, serves as a spin-off single that concludes the “THE SIN” series. This time, it tells the story of a couple who are convinced they share a fated relationship in yet another parallel world. With their previous release, “The X: Bliss,” ENHYPEN topped the Billboard 200, the main album chart in the U.S., and successfully achieved their fifth “double million-seller” as a group. Their agency, Belief Lab, stated, “‘The X: Parallel World’ is a single that reflects the members’ determination to repay ‘ENJIN’ (their fanbase) with music for their unwavering love and support throughout the year.”
Expectations are growing for additional shareholder returns from SamsungElectronics and SK hynix ahead of their upcoming record-breaking earnings announcements. This comes as the two companies’ combin…
Wanted Lab Inc.(376980)is hosting an in-person job fair to directly connect developers with companies in response to growing demand for "Chonbang Engineers" (FDE).
Photo courtesy of WantedLab Inc.…
SillaJen, Inc.(215600)has confirmed initial antitumor effects in a Phase 1 clinical trial of its new anticancer drug candidate, “BAL0891,” currently under development. In an interim analysis of patien…